STARGEN

Welcome to the Brand page for “STARGEN”, which is offered here for Gene therapy and prophylaxis products, proteins, vaccines, enzymes and enzyme preparations, anti-apoptopic and angiostatic and angiogenic molecules, all for the treatment of degenerative diseases of the eyes, including stargardt disease and other degenerative diseases of the eyes; pharmaceutical preparations for treatment of degenerative diseases of the eyes, including stargardt disease and other degenerative diseases of the eye; retroviral vector and retroviral vector manufacturing preparations, pharmaceutical and biochemical preparations for the treatment of degenerative diseases of the eyes, including stargardt disease and other degenerative retinal diseases; gene based pharmaceutical preparations for the treatment of degenerative diseases of the eyes;star gen;licensing of intellectual property in respect of gene therapy products;scientific and medical research and development in respect of diseases of the eye; genetic engineering services; biotechnology services, relating to gene therapy products, development of new technology for others in the field of biotechnology and medical research, development of new technologies for others for diagnosis and treatment of diseases of the eyes;.

Its status is currently believed to be active. Its class is unavailable. “STARGEN” is believed to be currently owned by “Oxford BioMedica plc”.